Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001558370-25-005333
Filing Date
2025-04-24
Accepted
2025-04-24 07:01:03
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A acrs-20250423xdefa14a.htm DEFA14A 16390
2 GRAPHIC acrs-20250423xdefa14a_bg001.jpg GRAPHIC 149576
3 GRAPHIC acrs-20250423xdefa14a_bg002.jpg GRAPHIC 115251
  Complete submission text file 0001558370-25-005333.txt   374925
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37581 | Film No.: 25863542
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)